Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  abiraterone acetate
Find trials that include:  Any drugs shown
Results 1-18 of 18 for your search:
Start Over
Enzalutamide with or without Abiraterone Acetate and Prednisone in Treating Patients with Castration-Resistant Metastatic Prostate Cancer
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A031201, NCI-2013-01737, CALGB-A031201, NCT01949337
An Efficacy and Safety Study of JNJ56021927 in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CR105505, NCI-2015-00725, 56021927PCR3001, NCT02257736
Abiraterone Acetate, Radiation Therapy, and Hormone Therapy in Treating Patients with Unfavorable-Risk Localized Prostate Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 20 to 80
Trial IDs: Pro00044071, NCI-2013-01803, NCT01717053
Abiraterone Acetate Alone, or Abiraterone Acetate and Degarelix, or Degarelix Alone in Treating Patients with Prostate Cancer Previously Treated with Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-187, NCI-2012-03130, c11-092, NCT01751451
Abiraterone Acetate and Prednisone in Treating African American and Caucasian Patients with Hormone-Resistant Metastatic Prostate Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: Pro00046383, NCI-2014-00260, 212082PCR2018, DUMC Pro00046383, NCT01940276
Abiraterone Acetate without Exogenous Glucocorticoids in Treating Patients with Progressive Hormone-Resistant Prostate Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-449, NCI-2014-00950, NCT02025010
Testosterone Therapy Followed by Enzalutamide or Abiraterone Acetate in Treating Patients with Prostate Cancer That Is Progressing on Combined Androgen Therapies
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: J1416, NCI-2014-01366, CIR00006889, CIR00011018, NA_00093344, NA_00093344 / CIR00011018, NCT02090114
Abiraterone Acetate with or without Cabazitaxel in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 14-046, NCI-2014-01894, c12-108, NCT02218606
Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients with Hormone-Resistant Prostate Cancer
Status: Not yet active
Phase: Phase II
Type: Treatment
Age: 19 and over
Trial IDs: UCDCC#260, NCI-2016-00779, NCT02807805
Androgen Receptor Antagonist ARN-509, Abiraterone Acetate, Prednisone, Degarelix, and Indomethacin in Treating Patients with Localized Prostate Cancer Before Surgery
Status: Not yet active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9628, NCI-2016-01027, NCT02849990
A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CR104358, NCI-2014-02010, 2014-001426-14, 56021927PCR1010, NCT02123758
Abiraterone Acetate in Treating Patients with Hormone-Resistant Prostate Cancer
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: 11-0709, NCI-2012-00116, NCT01543776
Circulating Tumors Cells in Predicting Response to Abiraterone Acetate in Patients with Metastatic, Hormone-Resistant Prostate Cancer
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-209, NCI-2013-02355, 212082PCR2009, NCT01961843
Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer
Status: Active
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: MCC-17981, NCI-2015-00648, 15.01.0005, NCT02415621
Start Over